Oral Medication

NAIROBI, 26 September 2011 (IRIN) - Access to treatment for a killer tropical disease that affects up to half a million people annually is being jeopardized by international inattention, despite the introduction of a new combination therapy, health expert

On September 26, 2011 the FDA issued its latest update regarding its ongoing investigation into whether drospirenone containing oral birth control pills are more dangerous than other forms of oral birth control. This follows earlier reports from the FDA t

DALLAS and NEW YORK, Sept. 28, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes,

A large-scale clinical trial evaluating whether daily use of an oral tablet or vaginal gel containing antiretroviral drugs can prevent HIV infection in women is being modified because an interim review found that the study cannot show that one of the stud

A Phase III trial for blood thinner Rivaroxaban (Xarelto) for individuals with acute coronary syndrome met its primary endpoint for efficacy. Rivaroxaban compared to placebo, significantly reduced the rate of myocardial infarction, cardiovascular death an